WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca (NYSE: AZN) today announced that BRILINTA® (ticagrelor) tablets received Plan Preferred Tier 2 formulary access on Medco Health Solutions’ National commercial formulary and Preferred Brand formulary status on its Medicare Part D drug list.
